Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing
Open Access
- 1 November 1982
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 22 (5) , 859-877
- https://doi.org/10.1128/aac.22.5.859
Abstract
Cefotetan is a new, potent, 7 alpha-methoxy cephalosporin (cephamycin). The in vitro activity of cefotetan tested in a multiphasic, collaborative study against 12,260 consecutive clinical isolates and 448 selected isolates showed 93% of Enterobacteriaceae, 90% of methicillin-susceptible Staphylococcus aureus (broth dilution), 83% of Bacteroides fragilis, and 72% of non-enterococcal streptococci to be inhibited by less than or equal to 8 micrograms/ml. Beta-Lactamase-producing and -nonproducing Haemophilus influenzae strains were inhibited by less than or equal to 1.0 micrograms/ml. Cefotetan's inhibitory spectrum paralleled those of the newest generation of cephems and exceeded those of cefoxitin and cefamandole. No useful activity was present against Streptococcus faecalis or Pseudomonas aeruginosa. Cefotetan was bactericidal without significant inoculum effect and was highly resistant to hydrolysis by Richmond-Sykes types I, III, and IV beta-lactamases. Hydrolysis of the chromogenic cephalosporin PADAC (pyridine-2-azo-p-dimethylaniline cephalosporin) by type I beta-lactamases was markedly inhibited by concentrations of cefotetan similar to those of the potent inhibitor dicloxacillin. Analysis of agar disk diffusion for several disk potencies and broth dilution susceptibility tests by regression and error rate-bounding methods produced preliminary tentative zone standards (30-micrograms disk, using minimal inhibitory concentration breakpoints of less than or equal to 8 micrograms/ml susceptible and greater than 32 micrograms/ml resistant, or 75-micrograms disk, using minimal inhibitory concentration breakpoints of less than or equal to 16 micrograms/ml susceptible and greater than or equal to 64 micrograms/ml resistant) of greater than or equal to 18 mm susceptible, less than or equal to 14 mm resistant, and 15 to 17 mm indeterminate. Staphylococcus aureus testing with the 30-micrograms disk is not recommended.This publication has 21 references indexed in Scilit:
- Transferable multiple antibiotic resistance in Haemophilus influenzaeJournal of Antimicrobial Chemotherapy, 1981
- Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1980
- In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strainsAntimicrobial Agents and Chemotherapy, 1980
- Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicinAntimicrobial Agents and Chemotherapy, 1980
- Collaborative Evaluation of a Proposed Reference Dilution Method of Susceptibility Testing of Anaerobic BacteriaAntimicrobial Agents and Chemotherapy, 1979
- In vitro antimicrobial activity of piperacillin and seven other β-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including β-lactamase producing strainsJournal of Antimicrobial Chemotherapy, 1979
- Beta-Lactamase Stability of HR 756, a Novel Cephalosporin, Compared to That of Cefuroxime and CefoxitinAntimicrobial Agents and Chemotherapy, 1978
- Partial Characterization of a Beta-Lactamase from Vibrio parahaemolyticus by a New Automated Microiodometric TechniqueAntimicrobial Agents and Chemotherapy, 1978
- The β-lactamases of Gram-negative bacteria and their rôle in resistance to β-lactam antibioticsJournal of Antimicrobial Chemotherapy, 1976
- Susceptibility Tests of Anaerobic Bacteria: Statistical and Clinical ConsiderationsThe Journal of Infectious Diseases, 1974